CSF-1R blockade does not affect mammary tumour growth or metastasis in KEP mice. We set out to assess the role of CSF-1-CSF-1R signalling, which is vital for macrophages 25 , in tumour progression in the KEP model, which spontaneously develops mammary tumours resembling human invasive lobular carcinomas (ILCs) at 6-8 months of age 24 . Similar to human ILCs, KEP tumours Recent studies have revealed a role for macrophages and neutrophils in limiting chemotherapy efficacy; however, the mechanisms underlying the therapeutic benefit of myeloid-targeting agents in combination with chemotherapy are incompletely understood. Here, we show that targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K14cre;Cdh1 F/F ;Trp53 F/F transgenic mouse model for breast cancer stimulates intratumoural type I interferon (IFN) signalling, which enhances the anticancer efficacy of platinum-based chemotherapeutics. Notably, anti-CSF-1R treatment also increased intratumoural expression of type I IFN-stimulated genes in patients with cancer, confirming that CSF-1R blockade is a powerful strategy to trigger an intratumoural type I IFN response. By inducing an inflamed, type I IFN-enriched tumour microenvironment and by further targeting immunosuppressive neutrophils during cisplatin therapy, antitumour immunity was activated in this poorly immunogenic breast cancer mouse model. These data illustrate the importance of breaching multiple layers of immunosuppression during cytotoxic therapy to successfully engage antitumour immunity in breast cancer.
P oor chemotherapy response is a major obstacle to successful cancer treatment. There is a growing appreciation for the influential role of the immune system on the success of cytotoxic anticancer therapy 1 . Although the adaptive immune system contributes to the therapeutic benefit of certain chemotherapeutic drugs in immunogenic tumour models 2 , it frequently fails to be unleashed by these same agents in less immunogenic transgenic mouse tumour models [3] [4] [5] , suggesting the involvement of immunosuppressive mechanisms. Indeed, macrophages and neutrophils are frequently the most abundant immune cells in tumours, and clinical studies have reported a correlation between these myeloid cells and poor chemotherapy efficacy 4, [6] [7] [8] [9] [10] . Experimental animal studies confirm a causal relationship between tumour-associated myeloid cells and poor chemotherapy response 4, 5, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . For example, inhibition of macrophages in mammary tumour-bearing MMTV-PyMT mice increases paclitaxel efficacy via activation of antitumour immunity 4, 5 . Notably, macrophage-targeting and neutrophil-targeting agents are currently under clinical evaluation [21] [22] [23] . Although promising, the aforementioned preclinical studies only show a transient therapeutic effect of combined myeloid cell targeting and chemotherapy. A deeper understanding of the mechanisms of action is needed to facilitate the rational design of therapeutic combination strategies that convert 'cold' non-T cell-inflamed tumours into 'hot' inflamed tumours, thus engaging durable antitumour immunity in otherwise poorly immunogenic tumours.
By combining in vivo intervention experiments and mechanistic studies in the K14cre;Cdh1 F/F ;Trp53 F/F (KEP) mouse model for spontaneous mammary tumorigenesis 24 with validation studies in tumour biopsies of patients treated with anti-colony-stimulating factor-1 receptor (anti-CSF-1R), here, we demonstrate that CSF-1R inhibition synergizes with platinum-based chemotherapy by unleashing an intratumoural type I interferon (IFN) response. Besides this anti-CSF-1R-mediated conversion of the tumour microenvironment (TME) into a type I IFN-enriched milieu, it takes breaching of an additional layer of immunosuppression to engage antitumour immunity during cytotoxic therapy.
Articles NaTuRe Cell BIology are strongly infiltrated by macrophages ( Supplementary Fig. 1a,b) . Whereas in the MMTV-PyMT breast cancer model it has been reported that two distinct macrophage populations reside within the TME: CD11b hi MHCII hi CD206 hi mammary tissue macrophages and CD11b lo MHCII hi CD206 lo tumour-associated macrophages (TAMs) 26 , in mammary tumours of KEP mice, all F4/80 + macrophages express high levels of CD11b, low levels of CD206 and only a proportion of these cells expresses major histocompatibility complex class II (MHCII) ( Supplementary Fig. 1c ). These differences in intratumoural macrophage phenotypes between mouse tumour models underscore the complexity of macrophage plasticity in different tumour contexts. In line with the macrophage influx, CSF-1 protein levels are increased in KEP tumours versus healthy mammary glands of age-matched wild-type littermates (Fig. 1a ). Both cancer cells and host cells in KEP tumours express Csf1 mRNA, whereas Csf1 mRNA is barely detectable in healthy mammary glands ( Fig. 1b) . CSF-1R is highly expressed on TAMs and to a lesser extent on infiltrating monocytes and neutrophils ( Supplementary Fig. 1d ), but not on other tumour-associated immune cells or CD45 − cells ( Supplementary Fig. 1d ).
To determine whether intratumoural macrophage accumulation depends on CSF-1-CSF-1R signalling and whether macrophages influence tumour outgrowth and dissemination, we treated tumour-bearing KEP mice with a chimeric mouse IgG1 antagonistic antibody (2G2) that binds to mouse CSF-1R with high affinity (dissociation constant (K d ) = 0.2 nM) or with a control antibody 21 . CSF-1R blockade strongly reduced the TAM population ( Fig. 1c,d ) and, as a result, also the total CD45 + population ( Supplementary Fig. 1e ). Treatment with anti-CSF-1R alone did not influence tumour-specific survival (Fig. 1f ) or spontaneous metastasis formation ( Supplementary Fig. 1f ). We also investigated the therapeutic activity of anti-CSF-1R in the KEP-based model of spontaneous breast cancer metastasis 27 . In this model, after orthotopic transplantation of a KEP-derived tumour piece followed by surgical removal of the outgrown tumour, mice develop overt multi-organ metastatic disease. Anti-CSF-1R was started either after a palpable mammary tumour had developed (continuous setting) or after mastectomy (adjuvant setting) and continued until the development of metastatic disease ( Supplementary Fig. 1g ). Regardless of the treatment schedule, metastasis-specific survival and metastatic burden in the lungs were similar between control and anti-CSF-1R groups ( Supplementary Fig. 1h ,i). Thus, anti-CSF-1R monotherapy fails to affect outgrowth and dissemination of KEP mammary tumours.
CSF-1R blockade in tumour-bearing KEP mice enhances the anticancer efficacy of platinum-based chemotherapy. We next tested the anticancer efficacy of anti-CSF-1R in combination with two conventional chemotherapeutics with a different mode of action: cisplatin, a platinum-based anticancer drug that crosslinks DNA and induces apoptosis, and docetaxel, an antimitotic agent that interferes with cell division through stabilization of microtubules. Successful blockade of the CSF-1R pathway during treatment of tumour-bearing KEP mice with chemotherapy and anti-CSF-1R was confirmed by the reduction in the number of TAMs (Fig. 1c,d and Supplementary Fig. 2a,b) . Interestingly, anti-CSF-1R synergized with cisplatin, resulting in prolonged survival compared to cisplatin + control antibody-treated mice ( Fig. 1f ). By contrast, no therapeutic synergy was observed in docetaxel + anti-CSF-1R-treated mice ( Supplementary Fig. 2c ). The therapeutic synergy observed upon cisplatin + anti-CSF-1R was associated with more necrosis in KEP tumours ( Fig. 1g ) but not with more cleaved caspase 3 + apoptotic cells ( Supplementary Fig. 2d ). Perhaps other mechanisms of cell death are involved or the timing of our analysis was suboptimal for this parameter. Furthermore, anti-CSF-1R monotherapy-and to a lesser extent, the combination with cisplatin-decreased the number of BrdU + -proliferating cells ( Fig. 1h ). No significant changes in the number and pericyte coverage of CD31 + microvessels, the amount of intratumoural DNA double-strand breaks and intratumoural cisplatin-adduct formation were observed at the time-point analysed ( Supplementary  Fig. 2e -h). As expected, none of these parameters was changed in the docetaxel setting ( Supplementary Fig. 2i -m).
To assess whether the anti-CSF-1R-mediated therapeutic synergy was unique to cisplatin or could be extended to drugs with a similar mechanism of action, we tested another platinum-containing drug, oxaliplatin, and also found that the survival benefit of oxaliplatin was improved by combined CSF-1R blockade ( Fig. 1i and Supplementary Fig. 2n ). These data demonstrate that anti-CSF-1R acts synergistically with platinum-based chemotherapeutic drugs to extend the survival of mammary tumour-bearing KEP mice.
CSF-1R inhibition alters the innate immune landscape of KEP tumours.
Macrophages are key orchestrators of the inflammatory TME 28 . Thus, we set out to assess the effect of anti-CSF-1R on the innate immune landscape of KEP tumours. Despite the strong reduction of CD11b + F4/80 + TAMs on anti-CSF-1R, up to 20% of the intratumoural CD45 + immune cells still expresses the macrophage marker F4/80 ( Fig. 1d ). Detailed analysis of this surviving CD11b + F4/80 + population revealed that an increased proportion of these cells expresses the inflammatory monocyte marker Ly6C compared to CD11b + F4/80 + cells in control antibody-treated tumours ( Fig. 2a and Supplementary Fig. 3a ). Moreover, the surviving CD11b + F4/80 + cells in cisplatin + anti-CSF-1R-treated tumours express elevated levels of the co-stimulatory molecules CD80 and CD86, slightly elevated MHCII levels, decreased levels of the chemokine receptors C-C chemokine receptor type 2 (CCR2) and CX3C chemokine receptor 1 (CX3CR1), and increased levels of programmed cell death 1 ligand 1 (PD-L1) compared to intratumoural CD11b + F4/80 + cells in cisplatin + control antibody-treated mice ( Fig. 2b-g ). Furthermore, in the independent orthotopically transplanted K14cre;Trp53 F/F (KP) mammary tumour model, intratumoural CD11b + F4/80 + myeloid cells remaining after CSF-1R inhibition display an altered phenotype corresponding to that in anti-CSF-1R-treated KEP tumours ( Fig. 2h-m) . Thus, anti-CSF-1R depletes the majority of CD11b + F4/80 + TAMs, whereas a small population of CD11b + F4/80 + cells with a distinct phenotype survives. To explore whether these surviving cells could derive from circulating monocytes, we transferred tdTomato + monocytes into control antibody or anti-CSF-1R-treated tumour-bearing KEP mice. After 4 d, the transferred monocytes that infiltrated tumours of anti-CSF-1R-treated, and not control antibody-treated, animals partially acquired the phenotype of the surviving intratumoural CD11b + F4/80 + cell population (that is, loss of CX3CR1 and elevated PD-L1 expression) ( Supplementary Fig. 3b-d) . These findings suggest that the surviving CD11b + F4/80 + cells in anti-CSF-1R-treated tumours may derive from newly recruited circulating monocytes, although other mechanisms cannot be excluded.
Whereas in treatment-naive KEP tumours the macrophage/neutrophil ratio is approximately 3/1, in anti-CSF-1R-treated tumours, either in the presence or absence of cisplatin, this ratio is reversed ( Fig. 1d,e ). However, the absolute number of intratumoural neutrophils was not increased upon CSF-1R inhibition ( Supplementary  Fig. 3e ). Anti-CSF-1R treatment induced an increase in the number of monocytes and a modest, but not significant, and very variable increase in the number of intratumoural eosinophils and mast cells ( Supplementary Fig. 3f-h ). Together, these data show that cisplatin + anti-CSF-1R synergy is accompanied by changes in the myeloid immune landscape of tumours. Most notably, anti-CSF-1R treatment resulted in a surviving population of CD11b + F4/80 + cells with an altered phenotype. 
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Macrophage blockade enhances cisplatin response by unleashing intratumoural type I IFN signalling. To better characterize the phenotype of the anti-CSF-1R-surviving intratumoural CD11b + F4/80 + cells, next-generation RNA sequencing (RNA-seq) analysis was performed on CD11b + F4/80 + cells sorted from cisplatin + control antibody-treated or cisplatin + anti-CSF-1R-treated tumours. Hierarchical clustering of the top 400 variable genes revealed that CD11b + F4/80 + cells from cisplatin + anti-CSF-1R-treated tumours displayed a different transcriptome profile, mainly characterized by a strong enrichment of genes involved in type I IFN signalling and type I IFN production, whereas cell-cycle-associated genes were reduced ( Fig. 3a,b ). Interestingly, CSF-1R expression levels were lower in the remaining CD11b + F4/80 + cells from cisplatin + anti-CSF-1R-treated tumours (fold change: −2,04; P = 3.63 × 10 −5 ), perhaps explaining why these cells resisted anti-CSF-1R therapy. In parallel, we also performed RNA-seq on flow-sorted Ly6G + Ly6C low neutrophils isolated from tumours of cisplatin + control antibodytreated and cisplatin + anti-CSF-1R-treated KEP mice. Hierarchical clustering of the top 400 variable genes within this data set revealed that anti-CSF-1R treatment also had a significant effect on the transcriptome profile of tumour-associated neutrophils ( Supplementary  Fig. 4a ). To ensure that these transcriptome alterations in neutrophils are not a direct effect of anti-CSF-1R on neutrophils, but rather an indirect consequence of macrophage targeting, we performed 
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NaTuRe Cell BIology gene set enrichment analysis (GSEA) of target genes of early growth receptor 2 (EGR2), a transcription factor downstream of CSF-1R signalling 29 . No differences were observed in the expression of EGR2 target genes between neutrophils isolated from anti-CSF-1R-treated and control antibody-treated tumours ( Supplementary Fig. 4b ),
suggesting that neutrophils are not directly influenced by anti-CSF-1R. Interestingly, BiNGO analysis of the top 100 upregulated and downregulated genes and Ingenuity pathway analysis of the differentially expressed genes revealed an enrichment in genes involved in type I IFN signalling in neutrophils isolated from Articles NaTuRe Cell BIology cisplatin + anti-CSF-1R-treated tumours versus cisplatin + control antibody-treated tumours ( Supplementary Fig. 4c,d and Supplementary Table 3 ). These data indicate that the therapeutic benefit of cisplatin + anti-CSF-1R is accompanied by induction of type I IFN-stimulated genes (ISGs) in both intratumoural CD11b + F4/80 + cells and neutrophils. We hypothesized that the enrichment of ISGs in these intratumoural immune populations was a consequence of increased levels of type I IFNs in KEP tumours upon CSF-1R blockade. Indeed, by using primers hybridizing to all Ifna genes, mRNA expression of Ifna, but not Ifnb, was increased in tumours of cisplatin + anti-CSF-1R-treated KEP mice compared to cisplatin + control antibodytreated mice (Fig. 3c ). In line with this, the mRNA levels of various intracellular pattern recognition receptors, such as Tlr3, Rig1 and Ifih1, whose signals induce type I IFN production, were upregulated in cisplatin + anti-CSF-1R-treated tumours compared to cisplatin + control antibody treatment (Fig. 3d) . Notably, the increase in type I IFN expression upon anti-CSF-1R was independent of chemotherapy treatment, as a similar intratumoural increase in Ifna expression was observed upon anti-CSF-1R alone (Fig. 3e ) or with docetaxel + anti-CSF-1R ( Supplementary Fig. 5a ). We also confirmed the increased expression of Ifna-and of two ISGs, Isg15 and Oas1a-upon anti-CSF-1R treatment in the independent KP-based tumour transplantation model and in inoculated MC38 colorectal adenocarcinoma tumours 21 (Fig. 3f,g and Supplementary Fig. 5b ,c). Together, these data demonstrate that anti-CSF-1R induces type I IFN in the TME.
To pursue the cellular source of type I IFN, we flow-sorted different cell populations from cisplatin and cisplatin + anti-CSF-1Rtreated KEP tumours ( Supplementary Fig. 5d ) and compared Ifna and Ifnb transcript levels. Plasmacytoid dendritic cells are known for their ability to produce type I IFN; however, as very few plasmacytoid dendritic cells-less than 0.1% of the total intratumoural immune population-are present in KEP tumours ( Supplementary  Fig. 5e ,f), we could not recover RNA of sufficient quality. Likewise, we did not obtain RNA of sufficient quality from sorted CD31 + endothelial cells. Only the CD11b + F4/80 + immune cell population displayed elevated Ifna expression levels upon CSF-1R blockade ( Fig. 3h and Supplementary Fig. 5g ,h). In line with these in vivo findings, in vitro treatment of bone marrow-derived macrophages (BMDMs) with anti-CSF-1R modestly induces Ifna levels after 24 h of culture ( Supplementary Fig. 5i ). These analyses suggest that the surviving population of intratumoural CD11b + F4/80 + cells is an important source of IFN-α in cisplatin + anti-CSF-1R-treated KEP tumours.
To dissect the functional significance of type I IFN signalling in the therapeutic benefit of cisplatin + anti-CSF-1R therapy, we blocked the IFN-α/β receptor subunit 1 (IFNAR1) in KEP mice. Whereas blockade of type I IFN signalling did not influence the anticancer efficacy of cisplatin, anti-IFNAR1 treatment completely abrogated the synergistic effect of cisplatin + anti-CSF-1R treatment (Fig. 4a ). These findings reveal that therapeutic targeting of macrophages with anti-CSF-1R in tumour-bearing KEP mice unleashes intratumoural type I IFN signalling, which enhances the therapeutic efficacy of cisplatin.
Emactuzumab treatment induces intratumoural type I ISGs in patients with cancer.
To validate our preclinical findings that CSF-1R blockade unleashes intratumoural type I IFN signalling in patients, we compared ISG expression levels in pre-treatment and on-treatment tumour biopsies from patients with advanced solid tumours treated with emactuzumab (RG7155), a humanized antihuman CSF-1R monoclonal antibody (NCT01494688) 21, 30 . Gene expression profiling was performed on tumour biopsies taken before the start of treatment and after 4 weeks of emactuzumab therapy. We assessed the expression level of a set of 28 ISGs that was selected based on the RNA-seq results from our KEP mouse model ( Fig. 3a, Supplementary Fig. 4a ,c,d and Supplementary Table 3 ). The intratumoural expression of all 28 selected ISGs was increased in emactuzumab on-treatment biopsies versus pre-treatment biopsies, of which 11 ISGs were significantly upregulated (Fig. 4b,c ). Thus, in line with our preclinical studies, these clinical findings indicate that CSF-1R blockade is a powerful strategy to augment intratumoural type I IFN signalling.
Combined CSF-1R inhibition and neutrophil depletion engages antitumour immunity that further improves the therapeutic benefit of cisplatin. Type I IFNs are emerging as key regulators of cancer growth and therapy response 31, 32 . Type I IFNs can affect cancer biology via different mechanisms, including the induction of anti-proliferative and pro-apoptotic effects on IFNAR + cancer cells 33, 34 . Indeed, exposure of a cell line derived from a spontaneous KEP mammary tumour to recombinant IFN-α1 results in a dosedependent decrease in colony-forming ability, also in combination with cisplatin, suggesting that type I IFNs have a direct inhibitory effect on KEP cancer cells ( Fig. 5 ). Because type I IFNs are also key orchestrators of antitumour immunity [33] [34] [35] , we hypothesized that the anti-CSF-1R-induced type I IFN-enriched TME may foster antitumour CD8 + T cell activity. However, we observed fewer numbers of tumour-infiltrating CD4 + or CD8 + T cells in cisplatin + anti-CSF-1R-treated tumours than in cisplatin + control antibody-treated tumours ( Supplementary Fig. 6a-c) , and the CD8/regulatory T cell ratio was not affected (Fig. 6a ). More natural killer (NK) cells were infiltrating the cisplatin + anti-CSF-1R-treated KEP tumours; however, the number of granzyme B + cells was not affected compared to cisplatin + control antibody treatment (Fig. 6b,c and Supplementary  Fig. 6d ). We previously reported that cisplatin efficacy is independent of the adaptive immune system 3 , and, in line with the lack of more intratumoural granzyme B + cells and T cells, here, we also show that antibody-mediated depletion of CD8 + T cells does not reduce the therapeutic efficacy of cisplatin + anti-CSF-1R therapy (Fig. 6d ). In addition, genetic ablation of the entire adaptive immune system by crossing KEP mice with Rag1 −/− mice did not affect therapeutic synergy (Fig. 6g) . These data indicate that the anti-CSF-1R-mediated conversion of the TME into a type I IFNenriched milieu in cisplatin-treated mice is not sufficient to successfully engage an endogenous antitumour T cell response.
We next hypothesized that it may be necessary to breach an additional layer of immunosuppression before antitumour immunity can be unleashed. The most abundant immune cell population in cisplatin + anti-CSF-1R-treated KEP tumours is neutrophils ( Fig. 1e) and we have previously reported that KEP tumour-educated neutrophils are very immunosuppressive 36 . To address whether neutrophils impede antitumour immunity in cisplatin + anti-CSF-1R-treated mice, we treated tumour-bearing KEP mice with the neutrophilspecific anti-Ly6G antibody (clone 1A8). Immunohistochemistry for S100A9 confirmed a reduction in the number of neutrophils in the lungs and to a lesser extent in the tumour ( Supplementary  Fig. 6e,f) . Cisplatin + anti-CSF-1R + anti-Ly6G treatment significantly improved tumour control and prolonged the survival of KEP mice compared to cisplatin + anti-CSF-1R therapy (Fig. 6e ). Whereas cisplatin + anti-CSF-1R temporarily stabilizes tumour outgrowth, we observed tumour shrinkage in six out of ten mice treated with cisplatin + anti-CSF-1R + anti-Ly6G, and the mammary tumours of two of these mice regressed completely during treatment ( Supplementary Fig. 6g,h) . Anti-Ly6G treatment alone failed to influence primary tumour growth in KEP mice as previously shown 36 , neither did the combination of anti-CSF-1R + anti-Ly6G ( Supplementary Fig. 6i ) nor did anti-Ly6G alter the efficacy of cisplatin (Fig. 6e ). Further characterization of cisplatin + anti-CSF-1R + anti-Ly6G-treated KEP tumours showed a significant reduction in the number of BrdU + -proliferating cells and γ-H2AX + Articles NaTuRe Cell BIology DNA-damaged cells ( Supplementary Fig. 6j,k) . No statistically significant differences were observed in the number of apoptotic cells, CD31 + vessels and cisplatin adducts ( Supplementary Fig. 6l-n) . Interestingly, the CD8/regulatory T cell ratio, the absolute number of NK cells and the absolute and relative number of granzyme B + immune cells were increased in cisplatin + anti-CSF-1R + anti-Ly6G-treated tumours compared to cisplatin + control antibody therapy (Fig. 6a-c and Supplementary Fig. 6d ). Importantly, the additional therapeutic benefit obtained by anti-Ly6G treatment was partially lost after antibody-mediated depletion of CD8 + T cells or Articles NaTuRe Cell BIology NK cells (Fig. 6e,f) and was completely abrogated when the same treatment was performed in KEP;Rag1 −/− mice (Fig. 6g ). Collectively, these data indicate that the combined anti-CSF-1R-mediated conversion of the tumour milieu into a type I IFN-enriched environment and the relieve of neutrophil-dependent immunosuppression fosters engagement of antitumour immunity in the anticancer effect of cisplatin in this poorly immunogenic mouse tumour model.
Discussion
There is a growing realization that immune-mediated mechanisms influence the responsiveness of tumours to chemotherapy 1 . Notably, macrophages actively interfere with the therapeutic efficacy of chemotherapy via several mechanisms in mouse tumour models, including suppression of antitumour immunity through IL-10 secretion 5 , secretion of chemoprotective proteases such as cathepsins 12 or secretion of lysophospholipids 15 that interfere with the DNA damage response. These macrophage-mediated chemotherapy resistance mechanisms are dependent on the production of soluble mediators from TAMs. Our study reveals a conceptually different mechanism of how therapeutic targeting of macrophages improves chemotherapy efficacy. Through in vivo mechanistic studies in the KEP transgenic mouse model for breast cancer, we demonstrate that macrophage inhibition with anti-CSF-1R induces intratumoural type I IFN signalling, which acts synergistically with cisplatin to inhibit tumour outgrowth and extend survival.
There is a growing interest in the effect of type I IFNs on cancer behaviour and response to immune checkpoint inhibitors, radiotherapy and chemotherapy 32, [37] [38] [39] . Besides being associated with an improved prognosis [40] [41] [42] , an intratumoural IFN signature in patients with breast cancer has been correlated with improved chemotherapy response 37 , and preclinical studies reported that type I IFN enhanced chemotherapy efficacy 37, 43 . However, IFN-related gene signatures have also been correlated with chemotherapy resistance 44 , consistent with a pleomorphic and still poorly understood role of type I IFN signalling in the tumour context. Importantly, impaired type I IFN signalling is a prominent feature of immune dysfunction in patients with cancer 45 . Our study reveals that anti-CSF-1R represents a powerful approach to induce intratumoural IFN signalling and to sensitize tumours to cisplatin. Notably, we find that anti-CSF-1R treatment in patients with cancer also results in increased intratumoural expression of ISGs, confirming our findings that anti-CSF-1R unleashes type I IFN response in tumours.
Our study shows that anti-CSF-1R depletes the majority of F4/80 + TAMs; however, a small intratumoural CD11b + F4/80 + population with a distinct phenotype survives. Interestingly, these surviving cells express lower levels of Csf1r and significantly higher Ifna mRNA levels than the CD11b + F4/80 + cells in untreated tumours, probably accounting for the increased Ifna levels in the tumours. A shift in macrophage phenotype was also observed in pancreatic cancer and glioblastoma models upon interference with the CSF-1-CSF-1R pathway [46] [47] [48] [49] . Similar to our model, targeting CSF-1 in the pancreatic cancer models on the one hand depleted TAMs and on the other hand reprogrammed the remaining macrophages to an antitumour phenotype. Interestingly, type I IFN was also found to Articles NaTuRe Cell BIology be increased in these macrophages 49 ; however, its effect was not functionally pursued in this study. These data, combined with our observation that IFN-α is also upregulated in anti-CSF-1R-treated MC38 colon adenocarcinoma tumours, indicate that anti-CSF-1R-mediated induction of type I IFNs is not limited to breast cancer, but extends to other cancer types. Type I IFNs can directly affect cancer cells by inducing apoptosis or blocking proliferation, or indirectly by stimulating antitumour immune responses or inhibiting angiogenesis 33 . In line with the observed in vivo reduction of proliferating tumour cells upon anti-CSF-1R therapy, our in vitro studies indicate that IFN-α1 can directly suppress KEP cancer cells. We did not observe an effect of CSF-1R inhibition on the number of intratumoural blood vessels or their pericyte coverage, excluding an angiogenesis effect. Despite a key role for type I IFNs in dictating antitumour immunity 31, 32 , the increase in the number of intratumoural type I IFNs was not sufficient to induce effective antitumour T cell responses. In line with the immunosuppressive phenotype of tumour-educated neutrophils in KEP mice 36 and in other models 50 , the additional ablation of neutrophils stimulated antitumour immunity. It may be surprising that we observed a therapeutic benefit of depletion of neutrophils with an IFN gene signature in cisplatin + anti-CSF-1R-treated KEP mice, whereas some studies have suggested that type I IFNs can induce antitumour properties in neutrophils 51 . However, in line with our data, a type I IFN transcriptional signature in neutrophils in malaria-infected hosts and in patients with active tuberculosis correlated with tissue damage and disease pathogenesis 52, 53 , suggesting that, in these settings, type I IFN signalling in neutrophils may contribute to their harmful actions. In addition, although type I IFNs are often considered to exert antitumour functions, several studies on chronic viral infections show negative-feedback mechanisms when persistently present in the environment by, for example, generating an immunosuppressive milieu 34, 54, 55 . Perhaps in our study a similar mechanism is involved, explaining why the cytotoxic activity of platinum-based chemotherapy is enhanced by type I IFNs, but at the same time, this therapeutic synergy is limited by an immunosuppressive programme. Although T cell activation was implicated in controlling tumour growth upon combined macrophage and neutrophil depletion in a mouse model for pancreatic cancer 20 , the full mechanism in the context of chemotherapy was not completely resolved. Our in vivo data demonstrate that, although the release of type I IFN is necessary for cisplatin + anti-CSF-1R therapeutic synergy, it takes further depletion of neutrophils to engage an antitumour immune response during cisplatin treatment.
Interestingly, the platinum-based drugs cisplatin and oxaliplatin synergized with anti-CSF-1R treatment, whereas docetaxel did not, despite the induction of IFN-α in the docetaxel setting. It will be important to mechanistically understand how the type of chemotherapy dictates its ability to act in synergy with type I IFN signalling. These insights will facilitate the development of optimal combination therapies of CSF-1R-targeting drugs or other type I IFN-inducing agents, including STING (stimulator of IFN genes) agonists 56 , with chemotherapeutic agents. To maximize the therapeutic benefit of cytotoxic therapy in poorly immunogenic tumour types, it will be critical to simultaneously target neutrophil-dependent immunosuppression.
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Methods
Mice. The generation and characterization of KEP mice have been previously described 24 and are commercially available via Taconic Biosciences. KEP mice were back-crossed onto the FVB/N background, and genotyping was performed by PCR analysis on tail-tip DNA as described 24, 36 . KEP mice were crossed with Rag1 −/− mice (FVB/N, a gift from L. Coussens, Oregon Health & Science University, Portland) to generate KEP;Rag1 −/− mice 3 . Female KEP and KEP;Rag1 −/− mice were monitored twice weekly for the spontaneous onset of mammary tumour formation by palpation starting at 4 months of age. Donor tumours from KEP and KP 24 mice were collected in ice-cold PBS, cut into small pieces and resuspended in DMEM F12 containing 30% FCS and 10% dimethyl sulfoxide and stored at −150 °C. The perpendicular tumour diameters of mammary tumours were measured twice a week using a caliper. Age-matched wild-type littermates were used as controls. Female FVB/N mice (10-12 weeks of age) were obtained from Charles River. mTmG mice 57 (back-crossed to the FVB/N background) express tdTomato ubiquitously and were used for the isolation of bone marrow monocytes. Mice were kept in individually ventilated cages at the animal laboratory facility of the Netherlands Cancer Institute (NKI; Amsterdam, the Netherlands). Food and water were provided ad libitum. Animal experiments were approved by the Animal Ethics Committee of the NKI and performed in accordance with institutional, national and European guidelines for animal care and use. The study is compliant with all relevant ethical regulations regarding animal research.
In vivo intervention studies. KEP mice bearing spontaneous mammary tumours were randomized over the treatment groups before initiation of the treatment. Mice were injected intraperitoneally with the chimeric (hamster/mouse) anti-CSF-1R antibody (clone 2G2, Roche Innovation Center Munich; single loading dose of 60 mg per kg followed by 30 mg per kg once a week); control antibody (IgG1, MOPC21, Roche Innovation Center Munich; single loading dose of 60 mg per kg followed by 30 mg per kg once a week); anti-Ly6G antibody (1A8, BioXCell; single loading dose of 400 μg followed by 100 μg three times a week); anti-IFNAR1 (MAR1-5A3, BioXCell; 100 μg three times a week); anti-CD8 (2.43, BioXCell; single loading dose of 400 μg followed by 100 μg three times a week); anti-NK1.1 (PK136, BioXCell; single loading dose of 400 μg followed by 100 μg three times a week); and IgG2a (C1.18.4, BioXCell; single loading dose of 400 μg followed by 100 μg three times a week). The maximum tolerated dose (MTD) dose of cisplatin (5 mg per kg; Accord Healthcare Limited) was administered intravenously every other week for a total of four cycles. The MTD dose of docetaxel (15 mg per kg; Accord Healthcare Limited) was administered intravenously every week for a total of four cycles. The MTD dose of oxaliplatin (6 mg per kg diluted in NaCl; Fresenius Kabi) was administered intravenously every 10 days for three cycles.
Anti-CSF-1R, control antibodies, anti-Ly6G, anti-CD8 and anti-NK1.1 treatment started when mammary tumours reached a size of 25 mm 2 ; and anti-IFNAR1, cisplatin, docetaxel and oxaliplatin treatment started when mammary tumours reached a size of 50 mm 2 . For survival curve experiments and end-stage analyses, antibody treatment continued until the tumour or the cumulative tumour burden reached a size of 225 mm 2 . For survival curve experiments, an event is defined as an animal with a cumulative tumour size of 225 mm 2 . The main cause of death of censored mice was ulcerated tumours or cisplatin-induced renal toxicity for cisplatin-treated mice.
For time-point analyses, mice were killed 1 d after the second chemotherapy injection (therapy-responsive phase) or at a tumour size of 100 mm 2 in chemotherapy-naive mice. To assess tumour cell proliferation, BrdU (50 mg per kg) was injected intraperitoneally into mice 90 min before being sacrificed.
KP tumour pieces were orthotopically transplanted into the mammary fat pad of 10-12-week-old FVB/N female mice. Before initiation of the treatment, mice were randomized over the experimental groups and treated either with control antibody or anti-CSF-1R as described above. Treatment started at a tumour size of 25 mm 2 and continued until the tumour reached a size of 100 mm 2 when the mice were sacrificed.
MC38 tumours were provided by Roche Innovation Center Munich. MC38 cells were subcutaneously injected into C57Bl6/N mice and, when the tumour volume reached 100 mm 3 , treated with either control antibody or anti-CSF-1R as described above. Mice were sacrificed 5 d after the second treatment 21 .
Intervention studies in the KEP-based spontaneous metastasis model. The orthotopic KEP-based spontaneous metastasis model was described previously in detail 27 . Briefly, KEP tumour pieces (1 × 1 mm) were orthotopically transplanted into 10-12-week-old FVB/N female mice. Mammary tumours were surgically removed once they reached a tumour size of 225 mm 2 , after which mice were monitored and sacrificed when they reached the humane end point due to clinically overt metastatic disease. Tumour-bearing recipient mice were treated either with control antibody or with anti-CSF-1R once the mammary tumours reached 5 mm 2 (continuous setting) or 3 d after mastectomy (adjuvant setting). Antibody treatment continued until recipient mice developed clinical signs of distress caused by metastatic disease (for example, respiratory distress).
Histology, immunohistochemistry, immunofluorescence and RNA in situ hybridization. All histochemical and immunohistochemical analyses, except NKp46 immunohistochemistry, were performed by the Animal Pathology facility at the NKI. NKp46 immunohistochemistry was performed at the Histology core facility within the Cancer Research UK Beatson Institute (Glasgow, UK). For histochemical analysis, formalin-fixed tissues were processed, sectioned and stained as described 27 . Briefly, tissues were fixed for 24 h in 10% neutralbuffered formalin, embedded in paraffin, sectioned at 4 μm and stained with haematoxylin and eosin (H&E) for histopathological evaluation. H&E slides were digitally processed using the Aperio ScanScope (Aperio). For the quantitative assessment of areas in the tumour that had lost viability, slides were analysed with ImageJ by quantifying the percentage of non-viable areas (defined as areas that lost cellularity) over the total tumour area. Histochemistry for mast cells was performed with Toluidine blue.
For immunohistochemical analysis, paraffin sections were cut and deparaffinized. Antibodies and antigen retrieval methods are described in Supplementary Table 1 . Cisplatin adduct staining was performed on frozen tissues embedded in OCT. Quantification of positive cells was performed manually by counting five high-power (40×) fields of view (FOVs) per tumour by two independent operators in a blinded manner. Samples were visualized with a BX43 upright microscope (Olympus) and images were acquired in bright field using cellSens Entry software (Olympus).
The percentages of metastasis-bearing spontaneous KEP mice were calculated based on the microscopic presence or absence of metastatic nodules in lungs and lymph nodes. In the metastasis model, the number of metastatic nodules in the lungs was based on cytokeratin 8 expression. Mice that developed overt metastatic disease were included in the analysis, and mice that were sacrificed because of local recurrence of the primary tumour were excluded.
Immunohistochemistry analysis for CD68 expression (1:2,000, clone KP1, Dako) was performed by the NKI-AvL Core Facility Molecular Pathology and Biobanking on formalin-fixed paraffin-embedded material of ILC breast cancer patients from the RATHER cohort 58, 59 enrolled at the NKI. Anonymized archival tissue was used according to national guidelines regarding the use of archival material and with approval of the NKI-AVL translational research board.
Immunofluorescence analysis was performed on formalin-fixed paraffinembedded material. The list of primary and secondary antibodies is provided in Supplementary Table 1 . Sections were counterstained with DAPI (4,6-diamidino-2-phenylindole) and visualized with a Leica SP5 confocal microscope. Images were taken with LAS AF software (Leica) and values were obtained by counting α-SMA + CD31 + cells and total CD31 + cells in six fields per tumour by two independent researches.
In situ detection of Csf1 mRNA was performed using the RNAscope 2.0 FFPE Assay (Advanced Cell Diagnostics) and performed according to the manufacturer's recommendations 60 .
Flow cytometry. KEP tumours were collected in ice-cold PBS and processed as described 61 . Briefly, samples were mechanically chopped using the McIlwain tissue chopper (Mickle Laboratory Engineering) and enzymatically digested with 3 mg ml −1 collagenase type A (Roche) and 25 μg ml −1 DNase I (Sigma) in serumfree medium for 1 h at 37°C in a shaking water bath. After washing, cells were stained with fluorochrome-conjugated antibodies ( Supplementary Table 1 ). For intracellular staining of granzyme B, single-cell suspensions were stimulated in IMDM containing 8% FCS, 100 IU ml −1 penicillin, 100 μg ml −1 streptomycin, 0.5% β-mercaptoethanol, 50 ng ml −1 PMA, 1 μM ionomycin and Golgi-Plug (1:1,000; BD Biosciences) for 3 h at 37 °C. Following surface antigen staining, samples were fixed and permeabilized (BD Biosciences) and stained for intracellular proteins. Data acquisition was performed on BD LSRII or BD LSRFortessa flow cytometer using DIVA software (BD Biosciences) and data analysis was performed using FlowJo software version 9.9.6.
Isolation of intratumoural cell populations.
Primary mammary tumours were harvested from KEP mice 1 d after two cycles of chemotherapy (±100 mm 2 ) or at end-stage (±225 mm 2 ), and single-cell suspensions were generated as described above. Enrichment of CD11b + cells was performed using magnetic columns (Miltenyi Biotec), as described previously 61 . Briefly, single-cell suspensions were stained with anti-CD11b-APC (1:200; clone M1/70, eBioscience) for 20 min and incubated with magnetic anti-APC MicroBeads according to the manufacturer's instructions (Miltenyi Biotec). CD11b + cells were isolated with LS columns (Miltenyi Biotec) according to the manufacturer's instructions. For the isolation of macrophages and neutrophils from tumours at the therapy-responsive phase, the enriched CD11b + fraction was stained with antibodies against Ly6G-FITC (1:200; clone 1A8, BD Biosciences), F4/80-PE (1:200; clone BM8, eBioscience) and Ly6C-ef450 (1:400; clone hk1.4, eBioscience). LIVE/DEAD fixable aqua dead cell stain (Thermo Fisher Scientific) was added 1:100 in PBS to exclude dead cells. CD11b + F4/80 + macrophages and F4/80 − Ly6G + Ly6C low neutrophils were isolated with the BD FACSARIA II sorter with DIVA software (BD Biosciences).
For the isolation of cell populations from end-stage tumours, we separated intratumoural CD11b + and CD11b − cells by magnetic cell sorting as described above. The CD11b − and CD11b + fractions were stained as described in Supplementary Table 1 Corresponding author(s): Karin E. de Visser Last updated by author(s): Jan 21, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection
For Flow cytometry data: data acquisition was performed on BD LSRII flow cytometer using Diva software version 8.0.1 (BD Biosciences). For isolation of immune cells: data acquisition was performed on BD FACSARIA II sorter with DIVA software version 8.0.1 (BD Biosciences) and BD FACSARIA FUSION sorter with DIVA software version 8.0.1 (BD Biosciences). For RNAseq of murine immune cell populations: according to the Ovation RNA-Seq system V2 and Encore Rapid library systems protocols (NuGen), RNA was converted into cDNA libraries, subsequently sequenced on a HiSeq 1500 system and demultiplexed using CASAVA v1.8 (Illumina). For the quantitative assessment of areas in the tumor that had lost viability: H&E slides were digitally processed using the Aperio ScanScope (Aperio, Vista, CA). For Luminex cytokine array: data acquisition was performed with Bio-Plex 200 reader, using Bio-Plex Manager 6.0 software (Bio-Rad). Immunohistochemistry images were acquired with cellSens Entry software v. 1.5 (Olympus). For immunofluorescence of CD31 and alpha-SMA, images were taken with LAS AF software version 2.7.4 (Leica) on Leica SP5 confocal microscope.
Data analysis
Statistical analyses were performed using GraphPad Prism 7 and 8 (GraphPad Software Inc., La Jolla, CA). Flow cytometry data analysis was performed using FlowJo software version 9.9.6. For the RNA-Seq analysis of murine samples, TopHat2 v2.0.11, Partek Genomics Suite v6.6, R (v3.3.1), Cytoscape (BiNGO, EnrichmentMap and Word Clouding plug-ins), Ingenuity Pathway analysis (QIAGEN) and BubbleGUM GSEA were used. The reactome and transcription factor target gene sets were obtained via the online available Molecular Signatures Database (MSigDB) of the Broad Institute. For Luminex cytokine array: data analysis was performed with Bio-Plex 200 reader, using Bio-Plex Manager 6.0 software (Bio-Rad). For the quantitative assessment of areas in the tumor that had lost viability, slides were analyzed with ImageJ (1.47t) For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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October 2018 Antibodies Antibodies used
The anti-CSF-1R antibody was provided by Roche Innovation Center Munich. A detailed list of antibodies used for immunohistochemistry, immunofluorescence and flow cytometry (including vendor, catalog number and dilution) is found in Supplementary Table 1-3 . In addition, we used: -CD68 (1:2000, clone KP1, Dako, catalog number:M0814) was performed by NKI-AvL Core Facility Molecular Pathology & Biobanking (CFMPB) on FFPE material of invasive lobular carcinoma breast cancer patients from the RATHER cohort. -other antibodies for flow cytometry: CD11b-APC (1:200; clone M1/70, eBioscience; catalog #17-0112-82), Ly6G-APC (1:200, clone 1A8, Biolegend, catalog #127614), IFNAR1-PE (1:200, clone MAR1-5A3, eBioscience, catalog#12-5945-82). For intervention studies: the chimeric (hamster/mouse) anti-CSF-1R antibody (clone 2G2, Roche Innovation Center Munich); control antibody (IgG1, MOPC21, Roche Innovation Center Munich); anti-Ly6G antibody (1A8, BioXCell, catalog# BE0075); anti-IFNAR1 (MAR1-5A3, BioXCell, catalog# BE0241); anti-CD8 (2.43, BioXCell, catalog#: BE0061); anti-NK1.1 (PK136, BioXCell, catalog#:BE0036);IgG2a (C1.18.4, BioXCell, catalog# BE0085).
Validation
All antibodies used, except for anti-CSF-1R antibody for intervention studies, are commercially available. Antibody-mediated depletion of immune cells was validated by the use of a non-competitive antibody. Antibodies used for IHC were validated by the Pathology facilities at the NKI and at the Research UK Beatson Institute. 
Eukaryotic cell lines
Wild animals
The study does not involve wild animals
Field-collected samples
The study does not involve field-collected samples
Ethics oversight
Animal experiments were approved by the Animal Ethics Committee of the Netherlands Cancer Institute and performed in accordance with institutional, national and European guidelines for Animal Care and Use.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
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Population characteristics
For the immunohistochemistry analysis of CD68 expression, we used FFPE archivial material of invasive lobular carcinoma breast cancer patients from the EU FP7 RATHER project (termed 'RATHER', http://www.ratherproject.com/) recruited at the NKI. Please 
Recruitment
Please note, that we did not recruit patients for this manuscript. We have analyzed archival patient samples that originally were
